» Articles » PMID: 15699726

Incidence of Vestibular Schwannoma and Neurofibromatosis 2 in the North West of England over a 10-year Period: Higher Incidence Than Previously Thought

Overview
Journal Otol Neurotol
Date 2005 Feb 9
PMID 15699726
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the incidence of vestibular schwannoma (VS) in sporadic, neurofibromatosis type 2 (NF2) germ-line and mosaic form in a 10-year period.

Study Design: Review of all incident cases of VS presenting to the four main neurosurgical centers for a population of 4.1 million from 1990 to 1999 and cross-referencing with the regional cancer registry.

Setting: Population based.

Patients: All patients presenting with VS detected on magnetic resonance imaging scan.

Results: A total of 419 sporadic and 64 NF2-related VS were identified over the study period. This represented an incidence of 10.4 per million per year for sporadic VS and 11.8 per million per year including NF2-related tumors. The incidence rose to 14 per million per year in the latter 5 years. The NF2 patient diagnoses represent an estimated birth incidence of 1 in 25,000, and 7% of the patients with VS had NF2, which is higher than previous estimates.

Conclusions: The incidence of VS is rising almost certainly due to increasing diagnosis in the magnetic resonance imaging era. At current rates, 1 per 1,000 individuals will be diagnosed with VS in their lifetime. More VS than previously thought are due to NF2, which may be because of recognition of mosaic forms of the disease.

Citing Articles

Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.

Tops A, Schopman J, Koot R, Gelderblom H, Putri N, Rahmi L Cancers (Basel). 2025; 17(3).

PMID: 39941885 PMC: 11817438. DOI: 10.3390/cancers17030519.


Genetic Alterations in Patients with -Related Schwannomatosis and Sporadic Vestibular Schwannomas.

Douwes J, van Eijk R, Maas S, Jansen J, Aten E, Hensen E Cancers (Basel). 2025; 17(3).

PMID: 39941762 PMC: 11816073. DOI: 10.3390/cancers17030393.


Clinical Presentation, Treatment Outcomes, and Demographic Trends in Vestibular Schwannomas: A 135-Case Retrospective Study.

Toader C, Radoi P, Ilie M, Covache-Busuioc R, Buica V, Glavan L J Clin Med. 2025; 14(2).

PMID: 39860488 PMC: 11766384. DOI: 10.3390/jcm14020482.


Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation.

Screnci M, Puechmaille M, Berton Q, Khalil T, Mom T, Coll G J Clin Med. 2024; 13(23).

PMID: 39685944 PMC: 11642482. DOI: 10.3390/jcm13237488.


Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.

Gregory G, Haley M, Jones A, Hannan C, Evans D, King A Brain Commun. 2024; 6(6):fcae400.

PMID: 39611183 PMC: 11604085. DOI: 10.1093/braincomms/fcae400.